Drug intelligence / Profile preview

16448

Development stage: Phase 2
Lead developer: GSK
Modality: Small Molecules

Overview

16448 is a small molecule drug initially developed by GSK for the treatment of urogenital diseases, specifically investigated for premature ejaculation. It has undergone Phase 2 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy males with primary premature ejaculation. The drug is noted to have a novel mode of action aimed at increasing ejaculatory latency time. As of the latest update, its highest global R&D status is pending and it has not received regulatory approval[1].

Targets

GSK3 (Glycogen synthase kinase 3 beta)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on 16448.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 16448.